XML 40 R30.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Equity (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Equity [Abstract] |
Schedule of Equity |
| Three Months Ended September 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at July 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 44,039 |  | $ | 48,777 |  | $ | (4,628) |  | 1,044 |  | $ | (56,682) |  | $ | 94 |  | $ | 33,388 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 4,567 |  | — |  | — |  | — |  | — |  | 4,567 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 38 |  | — |  | — |  | — |  | 38 |
Cash dividends declared on common stock ($0.65 per share) | — |  | — |  | — |  | (1,653) |  | — |  | — |  | — |  | — |  | (1,653) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 8 |  | (583) |  | — |  | (583) |
Share-based compensation plans and other | — |  | — |  | 110 |  | — |  | — |  | — |  | 21 |  | — |  | 131 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 4 |  | 4 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (29) |  | (29) |
Balance at September 30, 2021 | 3,577 |  | $ | 1,788 |  | $ | 44,149 |  | $ | 51,691 |  | $ | (4,590) |  | 1,052 |  | $ | (57,244) |  | $ | 69 |  | $ | 35,863 |
Balance at July 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 3,248 |  | — |  | — |  | — |  | — |  | 3,248 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (416) |  | — |  | — |  | — |  | (416) |
Cash dividends declared on common stock ($0.69 per share) | — |  | — |  | — |  | (1,757) |  | — |  | — |  | — |  | — |  | (1,757) |
Share-based compensation plans and other | — |  | — |  | 128 |  | — |  | — |  | — |  | 12 |  | — |  | 140 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 5 |  | 5 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (14) |  | (14) |
Balance at September 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,243 |  | $ | 59,928 |  | $ | (4,743) |  | 1,044 |  | $ | (56,758) |  | $ | 66 |  | $ | 44,524 |
| Nine Months Ended September 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at January 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,588 |  | $ | 47,362 |  | $ | (6,634) |  | 1,047 |  | $ | (56,787) |  | $ | 87 |  | $ | 25,404 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 9,291 |  | — |  | — |  | — |  | — |  | 9,291 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 1,595 |  | — |  | — |  | — |  | 1,595 |
Cash dividends declared on common stock ($1.95 per share) | — |  | — |  | — |  | (4,962) |  | — |  | — |  | — |  | — |  | (4,962) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 11 |  | (822) |  | — |  | (822) |
Spin-off of Organon & Co. | — |  | — |  | 4,643 |  | — |  | 449 |  | — |  | — |  | (1) |  | 5,091 |
Share-based compensation plans and other | — |  | — |  | (82) |  | — |  | — |  | (6) |  | 365 |  | — |  | 283 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 12 |  | 12 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (29) |  | (29) |
Balance at September 30, 2021 | 3,577 |  | $ | 1,788 |  | $ | 44,149 |  | $ | 51,691 |  | $ | (4,590) |  | 1,052 |  | $ | (57,244) |  | $ | 69 |  | $ | 35,863 |
Balance at January 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 11,502 |  | — |  | — |  | — |  | — |  | 11,502 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (314) |  | — |  | — |  | — |  | (314) |
Cash dividends declared on common stock ($2.07 per share) | — |  | — |  | — |  | (5,270) |  | — |  | — |  | — |  | — |  | (5,270) |
Share-based compensation plans and other | — |  | — |  | 5 |  | — |  | — |  | (5) |  | 351 |  | — |  | 356 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 6 |  | 6 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (13) |  | (13) |
Balance at September 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,243 |  | $ | 59,928 |  | $ | (4,743) |  | 1,044 |  | $ | (56,758) |  | $ | 66 |  | $ | 44,524 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration